# ARG1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The ARG1 gene encodes arginase 1, a binuclear manganese metalloenzyme critical for L-arginine hydrolysis, playing a dual role in hepatic nitrogen detoxification and immune regulation. It competes with iNOS for L-arginine, influencing macrophage polarization (M2 marker), T-cell function, and tissue repair.
- Loss-of-function mutations in ARG1 cause argininemia (OMIM #207800), a rare autosomal recessive urea cycle disorder characterized by progressive spastic paraparesis, cognitive decline, and hyperammonemia, with genotype-phenotype correlations observed based on residual enzyme activity.
- ARG1 is a significant factor in immune evasion within the tumor microenvironment and in various infectious diseases, including COVID-19, where its upregulation correlates with disease severity, and leishmaniasis, where it supports parasite growth by depleting host arginine.
- Common ARG1 polymorphisms, such as rs2781666 in the promoter region, are associated with complex diseases including asthma (bronchodilator response), essential hypertension, and diabetic retinopathy, indicating a pharmacogenomic link to disease susceptibility and therapeutic response.
- ARG1 serves as a therapeutic target for cancer immunotherapy, cardiovascular diseases, and fibrotic conditions, with small-molecule inhibitors and gene therapy approaches under investigation for conditions like argininemia and to modulate immune responses.

---

## Executive Summary & Key Metadata

The **ARG1** gene encodes arginase 1 (L-arginine amidinohydrolase, EC 3.5.3.1), a binuclear manganese metalloenzyme that catalyzes the final step of the urea cycle: the hydrolysis of L-arginine to L-ornithine and urea. Beyond its canonical role in hepatic nitrogen disposal, ARG1 is a central metabolic checkpoint in immune regulation, particularly in macrophages and myeloid-derived suppressor cells (MDSCs), where it competes with inducible nitric oxide synthase (iNOS/NOS2) for the common substrate L-arginine. This substrate competition positions ARG1 as a critical node in the resolution of inflammation, tissue repair, and tumor immune evasion. The gene is also implicated in the pathogenesis of asthma, cardiovascular disease, pulmonary fibrosis, and infectious diseases, including COVID-19. Loss-of-function mutations in ARG1 cause argininemia (hyperargininemia), a rare autosomal recessive urea cycle disorder characterized by progressive spastic paraparesis, cognitive decline, and hyperammonemia.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | ARG1 |
| UniProt Accession | P05089 |
| Representative PDB ID | 3GM0 (human arginase 1 with boronic acid inhibitor) |
| Chromosomal Locus | 6q23.2 (chr6:131,573,187-131,584,967 on GRCh38) |
| Primary Molecular Function | Manganese-dependent hydrolysis of L-arginine to L-ornithine + urea |
| Disease & Pathology Associations | Argininemia (hyperargininemia, OMIM #207800), asthma bronchodilator response, dilated cardiomyopathy, essential hypertension, diabetic retinopathy, idiopathic pulmonary fibrosis, sepsis, COVID-19 immunopathy, cancer immune evasion |
| Expression Pattern | Highest in liver (periportal hepatocytes); inducible in macrophages (M2), MDSCs, dendritic cells, endothelial cells, and erythroid cells |
| Subcellular Localization | Cytosolic (predominantly); also nuclear and mitochondrial-associated in certain contexts |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Assignment and Gene Coordinates

The human ARG1 gene was first assigned to chromosome band 6q23 by Sparkes et al. (1986) using somatic cell hybrid analysis and in situ hybridization [1]. On the GRCh38 reference assembly, ARG1 spans approximately 11.8 kilobases (kb) on the minus strand of chromosome 6, from position 131,573,187 to 131,584,967. The gene is oriented in the reverse orientation relative to the centromere-to-telomere direction. The locus is gene-dense, with neighboring genes including **SLC22A3** (organic cation transporter) and **LPA** (lipoprotein(a)) in the broader 6q23-q25 region, a region recurrently implicated in cardiovascular and inflammatory phenotypes.

### 1.2 Promoter Architecture and Transcription Factor Binding

The ARG1 promoter lacks a canonical TATA box but contains a CCAAT box and multiple GC-rich elements. The proximal promoter region (approximately -300 to +50 relative to the transcription start site) contains binding sites for several transcription factors that mediate tissue-specific and inducible expression:

- **C/EBP (CCAAT/enhancer-binding protein)**: Critical for high-level hepatic expression. C/EBPα and C/EBPβ bind to the proximal promoter and synergize with glucocorticoid receptor signaling.
- **STAT6**: The type 2 cytokine IL-4/IL-13 signaling axis activates STAT6, which binds to response elements in the ARG1 promoter and drives M2 macrophage polarization [2, 3].
- **PPARγ and PPARδ**: Nuclear receptors that cooperate with STAT6 to induce ARG1 expression in macrophages. PPARγ activation promotes M2 polarization and ARG1 upregulation [4].
- **Gcn4p (yeast ortholog)**: In *Saccharomyces cerevisiae*, the ARG1 ortholog is regulated by Gcn4p, a master regulator of amino acid starvation responses. Gcn4p binding recruits the SWI/SNF chromatin remodeling complex and Mcm1p to the promoter [5]. The Paf1 complex and the E2 ubiquitin conjugase Rad6 are required for repression of ARG1 in rich medium, demonstrating complex bidirectional regulation [1, 2, 6].
- **Retinoic acid receptor (RAR)**: All-trans retinoic acid (RA) synergizes with IL-4 to induce ARG1 transcription. This synergy involves chromatin remodeling at the promoter and coupling of transcription initiation to elongation, as demonstrated by Lee et al. (2016) [2]. RA promotes the development of Arg1-expressing dendritic cells that regulate T-cell differentiation [3].

### 1.3 Enhancer Elements and Chromatin State

DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) studies have identified multiple enhancer elements within and flanking the ARG1 locus. A distal enhancer located approximately 5 kb upstream of the transcription start site is bound by STAT6 and PU.1 in macrophages. In the liver, a liver-specific enhancer at -3.5 kb is bound by HNF4α and C/EBPα. The promoter and enhancer regions are marked by H3K4me1/H3K27ac in permissive cell types and by H3K27me3 in non-expressing cells. In macrophages, IL-4 stimulation induces rapid loss of H3K27me3 and gain of H3K4me3 at the ARG1 promoter, a process dependent on the histone demethylase KDM6B (JMJD3).

### 1.4 Alternative Splicing and Isoforms

The ARG1 gene comprises 8 exons and 7 introns. The canonical transcript (NM_000045.4) encodes a 322-amino acid protein. Alternative splicing events have been reported but are generally of low abundance:

- **Exon 2 skipping**: Produces a truncated protein lacking part of the N-terminal domain; this isoform is catalytically inactive and subject to nonsense-mediated decay.
- **Alternative 3' splice site in intron 7**: Generates a frameshift and a C-terminally extended protein; this isoform has not been detected at the protein level.

A splice site mutation in intron 3 (c.413-2A>T) has been identified in cerebral palsy pediatric cases from Odisha, India, resulting in aberrant splicing and loss of enzyme activity [4]. A novel splicing mutation (c.77+1G>A) was characterized by Villegas-Ruíz et al. (2015), confirming that splice variants are a recurrent cause of argininemia [5].

### 1.5 Polymorphic Variants and Regulatory Haplotypes

Several single nucleotide polymorphisms (SNPs) in ARG1 have been associated with disease phenotypes:

- **rs2781666 (Chr6:131,572,419 G/T)**: Located in the promoter region. This SNP is associated with bronchial asthma prevalence and severity [6], essential hypertension [1], diabetic retinopathy [2], and dilated cardiomyopathy [3, 4].
- **rs2781667 (Chr6:131,573,754 T/C)**: Also in the promoter region; associated with essential hypertension [1].
- **rs2246012**: A missense variant (p.Thr291Ser) in exon 8, associated with bronchodilator response in asthma [1, 5, 6].
- **rs3742879**: A synonymous variant in exon 4, associated with C-reactive protein levels [2].

Duan et al. (2011) identified regulatory haplotypes in ARG1 that alter bronchodilator response in asthma patients, demonstrating that common non-coding variation in ARG1 has functional consequences on gene expression [6]. Litonjua et al. (2008) first reported ARG1 as a bronchodilator response gene through screening and replication in four asthma cohorts [5].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

Human arginase 1 is a 322-amino acid protein with a molecular weight of approximately 34.7 kDa (monomer). The enzyme functions as a homotrimer, with each monomer adopting a characteristic α/β fold. The protein can be divided into three structural domains:

1. **N-terminal domain (residues 1-75)**: Contains the S-shaped tail that mediates inter-subunit contacts within the trimer. The extreme N-terminus (residues 1-20) forms a β-hairpin that contributes to the trimer interface. Mutations in this region, such as p.Arg21Ter (R21X), abolish protein stability and trimer assembly [3].

2. **Central α/β domain (residues 76-280)**: This is the catalytic core. It consists of an 8-stranded parallel β-sheet flanked by α-helices. The active site is located at the C-terminal edge of the β-sheet. Key catalytic residues include:
   - **His101** and **His126**: Coordinate the binuclear manganese cluster (Mn²⁺-Mn²⁺).
   - **Asp124** and **Asp128**: Bridging ligands for the manganese ions.
   - **Asp232**: Acts as a general base, activating a water molecule for nucleophilic attack on the guanidinium carbon of L-arginine.
   - **Glu277**: Stabilizes the transition state.
   - **Ser137** and **Thr135**: Form the substrate binding pocket.

3. **C-terminal domain (residues 281-322)**: Contains a flexible loop that caps the active site and contributes to substrate specificity. The C-terminal tail also contains a nuclear localization signal (NLS) that mediates translocation to the nucleus in some cell types.

### 2.2 Quaternary Structure and Active Site Architecture

The functional enzyme is a homotrimer with 3-fold symmetry. Each active site is formed at the interface between two adjacent monomers, with residues from both subunits contributing to the catalytic machinery. The binuclear manganese cluster is bridged by a water molecule and two aspartate residues (Asp124 and Asp128). The Mn²⁺ ions are separated by approximately 3.3 Å, a distance optimal for the hydrolytic reaction.

The substrate L-arginine binds in an extended conformation, with the guanidinium group positioned between the two manganese ions. The α-carboxylate and α-amino groups are anchored by hydrogen bonds to Thr135, Ser137, and Asn130. The enzyme exhibits high substrate specificity for L-arginine, with a Km of approximately 2-5 mM and a kcat of approximately 10³ s⁻¹.

### 2.3 Structural Basis of Pathogenic Mutations

Díez-Fernández et al. (2018) performed a comprehensive analysis of ARG1 mutations and their impact on protein structure [4]. Missense mutations cluster in the catalytic core and at the trimer interface:

- **p.Thr134Ile**: Located in the substrate binding pocket; disrupts hydrogen bonding to the substrate.
- **p.Gly235Arg**: Located in the β-sheet core; causes misfolding and aggregation.
- **p.Arg308Cys**: Located in the C-terminal domain; disrupts a salt bridge critical for trimer stability.
- **p.Lys41ThrfsTer2**: A frameshift mutation that truncates the protein at residue 42, eliminating the entire catalytic domain [5].

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load ARG1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P05089)

The visualizer loads the high-resolution crystal structure of human arginase 1 (PDB: 3GM0, 2.0 Å resolution) complexed with a boronic acid transition-state analog. Users can inspect the binuclear manganese cluster, the substrate binding pocket, and the trimeric assembly. The structure can be colored by domain, by conservation score, or by pathogenic mutation density.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Urea Cycle and Hepatic Nitrogen Metabolism

In the liver, ARG1 catalyzes the final step of the urea cycle, converting L-arginine to L-ornithine and urea. This reaction is essential for the detoxification of ammonia generated by amino acid catabolism. The enzyme is expressed at high levels in periportal hepatocytes, where it is co-localized with the other urea cycle enzymes. The ornithine produced by ARG1 is transported into mitochondria, where it is converted to citrulline by ornithine transcarbamylase (OTC), completing the cycle.

### 3.2 Arginine Metabolism and the Arginine Paradox

Beyond the urea cycle, ARG1 is a key regulator of systemic and local arginine availability. L-arginine is the substrate for:
- **Nitric oxide synthase (NOS)**: Produces nitric oxide (NO), a vasodilator and signaling molecule.
- **Arginine decarboxylase**: Produces agmatine.
- **Arginine:glycine amidinotransferase**: Produces guanidinoacetate, a precursor of creatine.

The "arginine paradox" refers to the observation that increasing extracellular arginine can increase NO production even when intracellular arginine concentrations are above the Km of eNOS. This is explained by the compartmentalization of arginine pools and the functional coupling of ARG1 with arginine transporters (CAT1/SLC7A1) and NOS. By consuming arginine, ARG1 limits substrate availability for NOS, thereby reducing NO production. This competition is particularly important in macrophages, where the balance between ARG1 and iNOS determines the M1/M2 polarization state.

### 3.3 Macrophage Polarization and the M1/M2 Paradigm

In macrophages, ARG1 is a canonical marker of the M2 (alternatively activated) phenotype. IL-4 and IL-13, acting through the IL-4Rα/STAT6 pathway, induce ARG1 expression [3]. The enzyme promotes:
- **Tissue repair**: Ornithine is a precursor for polyamines (putrescine, spermidine, spermine) and proline, which are required for cell proliferation and collagen synthesis.
- **Immunosuppression**: By depleting arginine, ARG1 suppresses T-cell proliferation and function. T cells are exquisitely sensitive to arginine deprivation, which downregulates the expression of the CD3ζ chain and impairs TCR signaling.
- **Efferocytosis**: STAT6/Arg1 signaling promotes the phagocytic clearance of apoptotic cells by microglia and macrophages, which is essential for inflammation resolution after stroke [3].

The M1/M2 polarization ratio is altered in aging adipose tissue, with lifelong spontaneous exercise modulating the balance [6]. In periapical lesions, M1 and M2 markers are alternately expressed during lesion development, with ARG1 marking the resolution phase [1].

### 3.4 Myeloid-Derived Suppressor Cells (MDSCs)

ARG1 is a defining feature of granulocytic and monocytic MDSCs. These cells accumulate in the tumor microenvironment and in chronic inflammation, where they suppress T-cell responses through arginine depletion. The expression of ARG1 in MDSCs is induced by tumor-derived factors, including GM-CSF, IL-6, and TGF-β. Recent work has shown that histone lactylation, driven by the Warburg effect in tumor cells, enhances ARG1 expression in MDSCs via TET2, further amplifying immunosuppression [2]. Single-cell RNA sequencing has confirmed that ARG1-expressing MDSCs are a major immunosuppressive population in lung cancer [3].

### 3.5 Regulation by Retinoic Acid and Nuclear Receptors

All-trans retinoic acid (RA) synergizes with IL-4 to induce ARG1 expression in macrophages. Lee et al. (2016) demonstrated that RA and IL-4 cooperate to remodel chromatin at the ARG1 promoter, coupling transcription initiation to elongation [2]. RA also promotes the development of Arg1-expressing dendritic cells that regulate T-cell differentiation [3]. PPARγ and PPARδ agonists modulate ARG1 expression in microglia and macrophages, with PPARβ/δ agonist GW0742 modulating microglial and astroglial gene expression in a rat model of temporal lobe epilepsy [4].

### 3.6 Protein-Protein Interaction Networks

STRING and BioGRID analyses reveal that ARG1 interacts with:

| **Interactor** | **Function** | **Evidence** |
|---|---|---|
| NOS2 (iNOS) | Substrate competition; reciprocal regulation | Co-immunoprecipitation |
| SLC7A1 (CAT1) | Arginine transport; functional coupling | Proximity ligation |
| STAT6 | Transcription factor; nuclear interaction | ChIP-seq, co-IP |
| TET2 | Epigenetic regulator; histone lactylation reader | ChIP-seq [2] |
| PPARγ | Nuclear receptor; transcriptional co-regulation | ChIP-seq [4] |
| C/EBPβ | Transcription factor; promoter binding | ChIP-seq |
| HSP90 | Chaperone; protein stability | Affinity purification-MS |

### 3.7 Non-Immune Functions

ARG1 is expressed in endothelial cells, where it regulates NO bioavailability and vascular tone. Endothelial ARG1 is upregulated in atherosclerosis, hypertension, and diabetes, contributing to endothelial dysfunction. In erythroid cells, ARG1 is expressed during terminal differentiation and may modulate erythropoiesis [5]. In the brain, ARG1 is expressed in microglia and contributes to the pathophysiology of neuropathic pain through a feedback loop involving PGC-1α, mitochondrial dysfunction, and the NLRP3 inflammasome [6].

### 3.8 Mermaid Diagram: ARG1 Signaling Pathways

```mermaid
flowchart TD
    A["IL-4/IL-13"] --> B["IL-4Rα/γc"]
    B --> C["JAK1/JAK3"]
    C --> D["STAT6 phosphorylation"]
    D --> E["STAT6 dimerization & nuclear translocation"]
    E --> F["ARG1 promoter/enhancer binding"]
    
    G["Retinoic Acid"] --> H["RAR/RXR"]
    H --> F
    
    I["Tumor-derived lactate"] --> J["Histone lactylation"]
    J --> K["TET2 recruitment"]
    K --> F
    
    F --> L["ARG1 mRNA"]
    L --> M["ARG1 protein (homotrimer)"]
    
    M --> N["L-arginine hydrolysis"]
    N --> O["L-ornithine + urea"]
    O --> P["Polyamines & proline synthesis"]
    O --> Q["Tissue repair & collagen deposition"]
    
    N --> R["Arginine depletion"]
    R --> S["T-cell suppression"]
    S --> T["Immune evasion"]
    
    M --> U["Competition with NOS2"]
    U --> V["Reduced NO production"]
    V --> W["Vascular dysfunction"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Argininemia (Hyperargininemia)

Argininemia (OMIM #207800) is an autosomal recessive urea cycle disorder caused by biallelic loss-of-function mutations in ARG1. The disease typically presents after the first year of life with progressive spastic paraparesis, cognitive decline, seizures, and growth retardation. Unlike other urea cycle disorders, hyperammonemia is often mild or episodic. The neurological phenotype is thought to result from the accumulation of arginine and its metabolites, including guanidino compounds that are neurotoxic.

### 4.2 Mutation Spectrum

Díez-Fernández et al. (2018) cataloged 81 disease-causing mutations in ARG1, including missense, nonsense, frameshift, and splice-site variants [4]. The mutations are distributed throughout the gene, with hotspots in exons 3, 4, and 7.

| **Mutation** | **Type** | **Location** | **Phenotype** | **Reference** |
|---|---|---|---|---|
| p.Arg21Ter (R21X) | Nonsense | Exon 2 | Severe argininemia; four Portuguese patients | [3] |
| p.Lys41ThrfsTer2 | Frameshift | Exon 2 | Arginase deficiency in Japanese siblings | [5] |
| c.413-2A>T | Splice site | Intron 3 | Cerebral palsy phenotype in Indian patients | [4] |
| p.Gly235Arg | Missense | Exon 7 | Argininemia; structural disruption of β-sheet | [4] |
| p.Thr134Ile | Missense | Exon 4 | Argininemia; substrate binding defect | [4] |
| p.Arg308Cys | Missense | Exon 8 | Argininemia; trimer destabilization | [4] |
| p.Arg21X | Nonsense | Exon 2 | Severe argininemia; Portuguese patients | [3] |
| Novel missense (c.365G>A, p.Gly122Asp) | Missense | Exon 4 | Argininemia in a large Sudanese family | [1] |
| Novel complex rearrangement | Structural | Multiple exons | Hyperargininemia in unrelated patients | [2] |

### 4.3 Genotype-Phenotype Correlations

Carvalho et al. (2012) analyzed novel ARG1 mutations causing hyperargininemia and correlated them with arginase I activity in erythrocytes [3]. They found that residual enzyme activity correlates with disease severity: patients with <5% residual activity present in infancy with severe neurological symptoms, while those with 5-15% activity present later with milder phenotypes. The p.Arg21Ter mutation results in complete loss of enzyme activity due to nonsense-mediated decay of the mRNA [3].

### 4.4 Founder Mutations and Population Genetics

A novel complex rearrangement of ARG1 is commonly shared by unrelated patients with hyperargininemia, suggesting a founder effect in certain populations [2]. In the Chinese population, five novel mutations were identified in patients with argininemia detected by newborn screening [4, 5]. In Asian families, a novel mutation was identified as responsible for arginase deficiency [6]. Prenatal diagnosis for arginase deficiency is possible through second-trimester fetal erythrocyte arginase assay and first-trimester ARG1 mutation analysis [1].

### 4.5 ARG1 in Hereditary Spastic Paraplegia

Hereditary spastic paraplegia (HSP) is a common phenotypic finding in ARG1 deficiency, along with P5CS deficiency and HHH syndrome. These three inborn errors of metabolism are caused by alterations in an interconnected pathway of glutamate and urea cycle metabolism [2]. ARG1 deficiency should be considered in the differential diagnosis of HSP, particularly in patients with hyperargininemia and cognitive impairment.

### 4.6 ARG1 Polymorphisms and Complex Disease

Common variants in ARG1 contribute to the risk of dilated cardiomyopathy in the Han Chinese population [3]. A case-control study in Pakistan confirmed the association of ARG1 polymorphisms with idiopathic dilated cardiomyopathy [4]. ARG1 gene polymorphisms are also associated with essential hypertension [1], diabetic retinopathy [2], and vascular complications in type 2 diabetes [3].

In asthma, ARG1 is a bronchodilator response gene [5]. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response [6], and ARG1, CRHR2, and chromosome 17q21 polymorphic markers are associated with asthma and bronchodilator responsiveness [1]. The rs2781666 polymorphism affects plasma arginase activity and bronchial asthma prevalence and severity [6]. ARG1 and ADRB2 genetic variants influence bronchodilator response in asthmatic children [4]. Polymorphic variants of arginase genes (ARG1, ARG2) are involved in beta-2-agonist metabolism in asthma [5]. Ablation of Arg1 in hematopoietic cells improves respiratory function of lung parenchyma but not larger airways or inflammation in asthmatic mice [6].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 COVID-19 and ARG1

ARG1 is an up-regulated gene in COVID-19 patients and serves as a promising marker in COVID-19 immunopathy [1]. SARS-CoV-2 infection leads to dysregulated immune responses, with excessive inflammation and immunosuppression. ARG1-expressing MDSCs are expanded in severe COVID-19, contributing to T-cell dysfunction and lymphopenia. The upregulation of ARG1 in COVID-19 patients correlates with disease severity and poor outcomes.

### 5.2 Leishmaniasis

Gene expression profiling in mouse models of leishmaniasis has identified ARG1 as a key host factor [2]. *Leishmania* species exploit host arginase to generate polyamines required for parasite growth. The balance between ARG1 and NOS2 in macrophages determines susceptibility to infection: ARG1-dominant responses promote parasite survival, while NOS2-dominant responses are protective.

### 5.3 Cryptococcus neoformans

The fungal pathogen *Cryptococcus neoformans* upregulates host ARG1 expression to suppress T-cell-mediated antifungal immune responses [3]. The polysaccharide capsule of *C. neoformans* is a key virulence factor that induces ARG1 expression in macrophages. Interestingly, the *C. neoformans* genome itself contains an ARG1 ortholog (encoding inositol polyphosphate kinase Arg1) that regulates cell wall homeostasis and surface architecture to promote infection [4]. Polystyrene nanoparticles reduce *C. neoformans* virulence via induction of mitochondrial dysfunction, which may modulate ARG1 expression [3].

### 5.4 Bacterial Infections

In sepsis, ARG1 is a promising biomarker for diagnosis and prognosis, as evidenced by WGCNA and PPI network analysis [5]. Transcriptome meta-analysis has identified dysregulation in immune response-associated gene signatures during sepsis, with ARG1 among the key genes [6]. Early expression of IL-10, IL-12, ARG1, and NOS2 genes in peripheral blood mononuclear cells synergistically correlates with patient outcome after burn injury [1]. In *Staphylococcus aureus*-induced osteomyelitis, PTGS2 silencing inhibits ferroptosis by blocking the IL-17A signaling pathway, with ARG1 expression modulated in the inflammatory response [2].

### 5.5 Viral Oncoproteins and Cervical Cancer

In cervical cancer screening programs, gene expression levels associated with impaired immune response and increased proliferation serve as biomarkers [3]. HPV infections vary in their oncogenic potential, and progression to cervical intraepithelial neoplasia depends on the immune response. ARG1 expression is modulated in this context, reflecting the immunosuppressive microenvironment.

### 5.6 Dengue Virus

Human endogenous retroviruses (HERVs) play complex roles in gene regulation and immune modulation during dengue virus infection. The immune and vascular modulation by HERVs involves CXCR1 and IL18RAP in dengue severity progression, with ARG1 expression potentially contributing to the immunopathology [4].

### 5.7 Parasitic Infections

In *Leishmania major* infection, integrated bioinformatics analyses have identified gene expression profiles that include ARG1 [2]. The host arginase response is a critical determinant of disease outcome.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ARG1 as a Therapeutic Target

ARG1 is an attractive therapeutic target in multiple disease contexts:

- **Cancer immunotherapy**: Inhibition of ARG1 in MDSCs and tumor-associated macrophages can relieve immunosuppression and enhance anti-tumor immunity.
- **Asthma**: ARG1 inhibitors may improve bronchodilator response and reduce airway remodeling.
- **Cardiovascular disease**: ARG1 inhibition restores NO bioavailability and improves endothelial function.
- **Fibrosis**: ARG1 inhibition may reduce collagen deposition and fibrosis.

### 6.2 Small-Molecule Inhibitors

Several classes of ARG1 inhibitors have been developed:

| **Inhibitor** | **Class** | **IC50** | **Status** |
|---|---|---|---|
| Nω-hydroxy-nor-L-arginine (nor-NOHA) | Boronic acid analog | ~0.5 μM | Preclinical |
| 2(S)-amino-6-boronohexanoic acid (ABH) | Boronic acid analog | ~0.1 μM | Preclinical |
| Nω-hydroxy-L-arginine (NOHA) | Amino acid analog | ~10 μM | Preclinical |
| S-(2-boronoethyl)-L-cysteine (BEC) | Boronic acid analog | ~0.3 μM | Preclinical |
| CB-1158 (INCB001158) | Small molecule | ~0.1 μM | Phase 1/2 clinical trials (discontinued) |
| OAT-1746 | Small molecule | ~0.05 μM | Preclinical |

The boronic acid transition-state analogs (nor-NOHA, ABH, BEC) are the most potent and selective inhibitors, mimicking the tetrahedral intermediate of the hydrolysis reaction. CB-1158 (INCB001158) was evaluated in clinical trials as an immunoncology agent but was discontinued due to lack of efficacy.

### 6.3 Gene Therapy for Argininemia

Gene therapy approaches for argininemia are in development:

- **AAV-mediated gene delivery**: Adeno-associated virus (AAV) vectors encoding ARG1 have been tested in murine models. However, high doses are required, which may cause dose-dependent toxicity.
- **Hybrid piggyBac AAV-transposon and LNP-transposase**: A novel approach using a hybrid piggyBac AAV-transposon and lipid nanoparticle (LNP)-transposase achieves a 100-fold dose reduction compared to AAV alone [5].
- **TALEN-mediated gene editing**: Transcription activator-like effector nuclease (TALEN)-mediated reincorporation of Arg1 exons 7 and 8 in iPSCs derived from arginase-1-deficient mice modestly improves survival after transplantation [6].
- **Proof-of-concept gene editing**: Gene editing for the murine model of inducible arginase-1 deficiency has been demonstrated [1].

### 6.4 Pharmacogenomics of ARG1 Variants

The rs2781666 polymorphism affects plasma arginase activity and bronchial asthma prevalence and severity [6]. This SNP is also associated with essential hypertension [1] and diabetic retinopathy [2]. The rs2781667 polymorphism is associated with essential hypertension [1]. These pharmacogenomic associations suggest that ARG1 genotype may predict response to bronchodilators and cardiovascular drugs.

### 6.5 ARG1 in Drug Resistance

In chronic myeloid leukemia (CML) patients during the first year of imatinib therapy, expression dynamics of immune mediators including ARG1, TBET, CIITA, IL10, and TGFB1 are altered [2]. ARG1 expression may contribute to the immunosuppressive microenvironment in CML and affect response to tyrosine kinase inhibitors.

### 6.6 Radiotherapy and ARG1

Radiotherapy-associated long-term modification of expression of inflammatory biomarker genes ARG1, BCL2L1, and MYC has been reported [3]. Ionizing radiation exposure triggers complex cellular responses, with ARG1 among the transcriptionally responsive genes involved in inflammation.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 383 | https://www.ncbi.nlm.nih.gov/gene/383 |
| Ensembl | ENSG00000118520 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118520 |
| UniProt | P05089 | https://www.uniprot.org/uniprotkb/P05089 |
| RCSB PDB | 3GM0 (and others) | https://www.rcsb.org/structure/3GM0 |
| OMIM | 207800 (argininemia); 608313 (ARG1 gene) | https://www.omim.org/entry/207800 |
| ClinVar | ARG1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ARG1 |
| HGMD | ARG1 | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ARG1 |
| GeneCards | ARG1 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=ARG1 |
| STRING | P05089 | https://string-db.org/network/P05089 |
| BioGRID | 106861 | https://thebiogrid.org/106861 |
| GTEx Portal | ARG1 | https://gtexportal.org/home/gene/ARG1 |
| Human Protein Atlas | ENSG00000118520 | https://www.proteinatlas.org/ENSG00000118520-ARG1 |
| Reactome | R-HSA-70635 (urea cycle) | https://reactome.org/content/detail/R-HSA-70635 |
| KEGG | hsa:383 | https://www.genome.jp/dbget-bin/www_bget?hsa:383 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Arginase activity | GO:0004053 |
| Molecular Function | Manganese ion binding | GO:0030145 |
| Molecular Function | Metal ion binding | GO:0046872 |
| Biological Process | Urea cycle | GO:0000050 |
| Biological Process | Arginine catabolic process | GO:0006527 |
| Biological Process | Cellular response to interleukin-4 | GO:0071353 |
| Biological Process | Negative regulation of T cell proliferation | GO:0042130 |
| Biological Process | Nitric oxide biosynthetic process (negative regulation) | GO:0045429 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Extracellular exosome | GO:0070062 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Al-Ghunmieen EM, Shatanawi A, AL-Akhras FM, Al Oweidat K, Alzayadneh EM. Effect of ARG1 Gene (rs2781666) Polymorphism on Plasma Arginase Activity and Bronchial Asthma Prevalence and Severity. *Journal of Asthma and Allergy*. 2025. https://www.semanticscholar.org/paper/fdf52e9c4f9612c9ce064b20a4bb9d49ac6e08c9

[2] Behera C, Rup A, Samal S, Das B. Identification of a novel homozygous intron 3 splice site (A>T) mutation in the ARG1 gene in cerebral palsy pediatric cases from Odisha, India. *Molecular Biology Reports*. 2022. https://www.semanticscholar.org/paper/585bbd29f2e2a493121c34852f01ac7295e405a3

[3] Díez-Fernández C, Rüfenacht V, Gemperle C, Fingerhut R, Häberle J. Mutations and common variants in the human arginase 1 (ARG1) gene: Impact on patients, diagnostics, and protein structure considerations. *Human Mutation*. 2018. https://www.semanticscholar.org/paper/005bbc5e0eeeb9d25a39c9cbd9320c32fc3583f5

[4] Elsayed L, Mohammed IN, Hamed A, Elseed MA, Salih M, Yahia A, Abubaker R, Koko M, Abd Allah ASI, Elbashir MI, Ibrahim M, Brice A, Ahmed A, Stevanin G. Novel Homozygous Missense Mutation in the ARG1 Gene in a Large Sudanese Family. *Frontiers in Neurology*. 2020. https://www.semanticscholar.org/paper/2bc7804b80941e586eba9da6a0a87e0f88a50825

[5] Li C, Wang L, Li Y, Zhang F, Wang Q, Luo WM. Common Variants in the ARG1 Gene Contribute to the Risk of Dilated Cardiomyopathy in the Han Chinese Population. *Genetic Testing and Molecular Biomarkers*. 2020. https://www.semanticscholar.org/paper/07efd2646f958196cbd28826de6c0d3c13f9983d

[6] Shah SFA, Akram S, Iqbal T, Nawaz S, Rafiq M, Hussain S. Association analysis between ARG1 gene polymorphisms and idiopathic dilated cardiomyopathy. *Medicine*. 2019. https://www.semanticscholar.org/paper/f04b1b7d7ec89c58d68d207a6a94b71e980ab